长期核苷酸（T）IDE治疗（恩替卡韦，拉米夫定）在慢性乙型

StephenW

Long Term Nucleo(t)ide Treatment (entecavir, lamivudine) Reduces Mortality in Chronic Hepatitis B Patients                                     Reported by Jules Levin AASLD Nov 1-5 2013 Wash DC

                                                                       

StephenW

抗病毒药物，在乙肝患者死亡率降低：研究人员在与恩替卡韦（博路定）治疗472例，791例患者治疗与拉米夫定（拉米HBV）加上阿德福韦（阿德福韦酯），和1,141名未经治疗的乙肝患者相比死亡率长达九年如果抗病毒药物延长了生命的人感染乙肝病毒。

在研究过程中，恩替卡韦组死亡2例（0.7％），死亡8例（2.9％）拉米夫定组，对照组死亡68例（24.9％）。五年生存率分别为99.1％，97.6％和92.2％，恩替卡韦，拉米夫定治疗组和对照组分别。

日本研究人员认为，抗病毒药物（尤其是肝硬化患者）乙肝患者的死亡率大大降低。
控制ID1736731。长期的核苷（酸）IDE模拟治疗慢性乙型肝炎患者的肝相关死亡率降低。 （摘要编号925）

Christine K Kukka, hbvadvocate.org.
Antivirals reduce death rates among hepatitis B patients: Researchers compared death rates in 472 patients treated with entecavir (Baraclude), 791 patients treated with lamivudine (Epivir-HBV) plus adefovir (Hepsera), and 1,141 untreated HBV patients for up to nine years to see if antivirals extended the lives of people infected with HBV.

Over the course of the study, two patients (0.7%) in the entecavir group died, eight (2.9%) died in the lamivudine group, and 68 (24.9%) died in the control group. The five-year survival rates were 99.1%, 97.6% and 92.2% in the entecavir, lamivudine and control groups respectively.

Japanese researchers concluded that antivirals (especially in cirrhotic patients) greatly reduce death rates in hepatitis B patients.
Control ID 1736731. Long-term nucleos(t)ide analog treatment reduces liver related mortality in chronic hepatitis B patients. (Abstract #925)